$GILD News 10 stocks loved by advisers who beat bear

New Post Public Reply Private Reply Replies (0) Message Board

Oct 20, 2014 at 11:31 AM

$GILD News

10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Gilead’s new drug is even pricier than Sovaldi 5:29 p.m. Oct. 10, 2014 - Russ Britt
The most profitable companies get the best stock returns 8:31 a.m. Oct. 10, 2014 - Philip van Doorn
Bristol-Myers drops Hepatitis C dual regimen in U.S. 11:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
Mylan boosts full-year outlook on product launches 8:11 a.m. Oct. 3, 2014 - MarketWatch.com
During times like these, cash is king 2:03 p.m. Oct. 2, 2014 - The Trading Deck
Sovaldi pricing raises debate over drug costs 2:57 p.m. Oct. 1, 2014 - Jani Actman of Medill News Service
It’s crucial to watch growth stocks right now 3:06 p.m. Sept. 25, 2014 - The Trading Deck
Gilead Sciences shares up 1.5% 9:39 a.m. Sept. 25, 2014 - Sue Chang
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Market pullbacks present promise, not peril 1:58 p.m. Sept. 16, 2014 - The Trading Deck
Gilead Sciences shares slide 2.6% 9:39 a.m. Sept. 15, 2014 - Sue Chang
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore

Stocks Slide on Indiscriminate Selling 51 min ago - Barrons.com
LabCorp launches new HIV test 51 min ago - Seeking Alpha
Gilead: Stage Set For Rally 8:27 a.m. Today - Seeking Alpha
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies 7:40 a.m. Today - Seeking Alpha
Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14) 6:24 a.m. Oct. 19, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors 6:00 a.m. Oct. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:16 p.m. Oct. 17, 2014 - TheStreet.com
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog 4:30 p.m. Oct. 17, 2014 - Zacks.com
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now 1:54 p.m. Oct. 17, 2014 - Seeking Alpha
Health Canada issues notice of compliance for Gilead's Harvoni(TM) (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C 2:44 p.m. Oct. 16, 2014 - CNW Group
2 Companies That Don't Deserve This Market Beatdown 8:14 a.m. Oct. 16, 2014 - Seeking Alpha
Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog 5:20 p.m. Oct. 15, 2014 - Zacks.com
Best U.S. Stock Ideas Today 3:57 p.m. Oct. 15, 2014 - Seeking Alpha
Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark' 3:42 p.m. Oct. 15, 2014 - benzinga.com
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog 1:59 p.m. Oct. 15, 2014 - Zacks.com
Healthcare ETFs in Focus on JNJ Earnings Beat - ETF News And Commentary 1:00 p.m. Oct. 15, 2014 - Zacks.com
A Review Of Gilead's Harvoni, And Competitive Considerations 11:20 a.m. Oct. 15, 2014 - Seeking Alpha
Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths 9:35 a.m. Oct. 15, 2014 - TheStreet.com
Gilead Has Taken A Pounding But Is Almost At A Level That I Want To Buy 7:48 a.m. Oct. 15, 2014 - Seeking Alpha
'Fast Money' Recap: Now May Be the Time to Buy Energy Stocks 5:00 a.m. Oct. 15, 2014 - TheStreet.com

Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Today - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 6:23 a.m. Sept. 19, 2014 - BusinessWire - BZX
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer 6:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’ 6:21 p.m. Sept. 16, 2014 - BusinessWire - BZX
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C 5:50 p.m. Sept. 16, 2014 - Marketwire
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries 6:30 a.m. Sept. 15, 2014 - BusinessWire - BZX
Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries 6:30 a.m. Sept. 15, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Smart: Support Wildlife, Avoid Exploitation

Rethink Wildlife Tourism for Ethical Travel You ever stopped to think about what those so-called wildlife attractions are really selling? It’s a feel-good illusion wrapped up in exploitation. Travelers often see animals as part of the backdrop of their holiday stories, but the reality is far from picturesque. Behind the photo ops, there's typically a grim story of...

Graphic Packaging Names Berardinelli as HR Executive

A New Chapter in HR Leadership at Graphic Packaging September 8 marks a turning point for Graphic Packaging Holding Company with the appointment of Tatiana Berardinelli as their new Chief Human Resources Officer. As NYSE:GPK positions itself for ambitious growth, Berardinelli stands out for her knack for managing transformations and building cultures that thrive in...

Aristocrat's Tiki Fire Slots Heat Up North America

The Polynesian Flame Ignites: Tiki Fire Hits Online Games Just when you thought the iGaming world was catching its breath, Aristocrat Interactive throws another curveball. The buzz around their Lightning Link™ series, especially the launch of High Stakes™ in July, took the scene by storm. Now, just in time for another sizzle, they've rolled out Tiki Fire™, bringing...

Finzly Launches AI Security Layer Amid Rising Threats

Bank Security in the Age of AI You'd think banks, of all places, were impenetrable fortresses. But these days, they're more like digital targets. With AI-driven attacks becoming as common as morning coffee, Finzly's introducing Assure, an AI-powered security and assurance layer. It's about as timely as ever, given the 89% spike in AI-enabled attacks seen last year. When...

YSL Beauty’s Block Party Series Rocks London's Scene

YSL Beauty: More Than a Brand, a Cultural Movement London felt a distinct pulse this past weekend as YSL Beauty kicked off another sizzling event in its Block Party series. This one wasn't just another Instagrammable gathering; it was the kind of scene that shifted the cultural needle. What started in Madrid has now become a roving spectacle that sweeps across cities,...

Safety and Wellbeing as Key Business Strategy Focus

Revolutionizing Safety in the Workplace Cracking the typical mindset of treating employee safety as a checkbox item, Debra Wein, CEO and Founder of Wellness Workdays, is set to shake up the NSC Safety Congress & Expo. Her upcoming session, titled "Transforming Safety and Wellbeing into a Competitive Business Advantage," isn't just a run-of-the-mill talk. It's a call to...

Armed Security: Balancing Safety with Cost in Rochester

The Decision to Arm: When Business Risks Demand It You know, deciding whether to hire armed security isn't as clear-cut as some folks make it seem. It ain't just about slapping a guard at your door. There's a whole set of chess moves behind it, especially in good ol' Rochester. When you're juggling high-risk operations, like handling valuable inventory or dealing with...

Nonprofit Option Rises for Specialty Physicians

Reimaging Choices for Specialty Physicians In the whirlwind of healthcare, specialty physicians often find themselves between a rock and a hard place. The traditional paths are either hug a major health system or auction off to private equity, each option chaining them to systems more interested in the balance sheet than in patient care. But now, a third door opens. One...

Curaleaf Eyes Growth: Conference Signals Opportunities

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Photronics Faces Legal Heat: Key Investor Steps Now

Eyes on Photronics: A Legal Quake Anytime you hear a stock price nosedive like a kamikaze just blew up its own runway, it ought to set off every investor's alarms. And if you’re tied into Photronics (NASDAQ:PLAB), buddy, it's time to catch up on what's driving this train off the rails. With a class period stretching from December 2025 through May 2026, the dish is a...